Skip to content
10-K

Annual Report

TRILLIUM THERAPEUTICS INC.

0001104659-21-038350

← back to feed
Filed
Mar 18, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Mar 16, 2021 103.03M sh
Operating Cash Flow FY 2020 · Dec 31, 2020 −$22.73M
Operating Cash Flow FY 2020 · Dec 31, 2019 −$24.75M
Cash And Equivalents FY 2020 · Dec 31, 2020 $247.6M
Cash And Equivalents FY 2020 · Dec 31, 2019 $14.58M
Stockholders Equity FY 2020 · Dec 31, 2020 $278.85M
Stockholders Equity FY 2020 · Dec 31, 2019 −$1.33M
Stockholders Equity FY 2020 · Dec 31, 2018 $27.58M
Current Liabilities FY 2020 · Dec 31, 2020 $21.42M
Current Liabilities FY 2020 · Dec 31, 2019 $26.9M
Total Liabilities FY 2020 · Dec 31, 2020 $21.98M
Total Liabilities FY 2020 · Dec 31, 2019 $27.73M
Current Assets FY 2020 · Dec 31, 2020 $298.53M
Current Assets FY 2020 · Dec 31, 2019 $23.29M
Total Assets FY 2020 · Dec 31, 2020 $300.82M
Total Assets FY 2020 · Dec 31, 2019 $26.39M
Sga Expense FY 2020 · Dec 31, 2020 $36.26M
Sga Expense FY 2020 · Dec 31, 2019 $5.72M
Rd Expense FY 2020 · Dec 31, 2020 $25.35M
Rd Expense FY 2020 · Dec 31, 2019 $26.69M
Net Income FY 2020 · Dec 31, 2020 −$59.35M
Net Income FY 2020 · Dec 31, 2019 −$38.08M
Operating Income FY 2020 · Dec 31, 2020 −$61.46M
Operating Income FY 2020 · Dec 31, 2019 −$32.29M
Revenue FY 2020 · Dec 31, 2020 $148K
Revenue FY 2020 · Dec 31, 2019 $124K
Capex FY 2020 · Dec 31, 2019 $324K